Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
Public ClinicalTrials.gov record NCT01475786. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Engensis (VM202) in Subjects With Painful Diabetic Peripheral Neuropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if Engensis (VM202) is safe and effective in treating painful diabetic neuropathy.
Study identification
- NCT ID
- NCT01475786
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- Low Dose: 16 mg Engensis (VM202) Biological
- High Dose: 32 mg Engensis (VM202) Biological
- Control- Placebo (normal saline) Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2012 (Type not available)
- Primary completion
- Mar 12, 2014 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Oct 6, 2025
2012 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Diablo Clinical Research | Walnut Creek | California | 94598 | — |
| Compass Research | Orlando | Florida | 32806 | — |
| Palm Beach Neurological Center | Palm Beach Gardens | Florida | 33418 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| Beth Israel Deaconess | Boston | Massachusetts | 02115 | — |
| The Neurosciences Institute Albany Medical College | Albany | New York | 12208 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| University of Oklahoma Harold Hamm Diabetes Center | Oklahoma City | Oklahoma | 73104 | — |
| Houston Neurocare | Houston | Texas | 77030 | — |
| The Methodist Hospital | Houston | Texas | 77030 | — |
| University of Utah | Salt Lake City | Utah | 84132 | — |
| East Virginia Medical School Strelitz Diabetes Center | Norfolk | Virginia | 23510 | — |
| Rainier Clinical Research | Seattle | Washington | 98057 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01475786, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2025 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01475786 live on ClinicalTrials.gov.